SJIF Impact Factor: 6.711

WORLD JOURNAL OF ADVANCE HEALTHCARE RESEARCH

ISSN: 2457-0400
Volume: 8.
Issue: 5
Page N. 171-186
Year: 2024

Review Article www.wjahr.com

EXPLORING THE PHARMACOKINETIC PROPERTIES AND METABOLIC PATHWAYS OF BENZOTHIAZOLE AND OXAZOLE-BASED COMPOUNDS: IMPLICATIONS FOR DRUG OPTIMIZATION AND DEVELOPMENT

Uriti Sri Venkatesh[1], Raghav Dixit[2], Vilas Nilkanthrao Deshmukh[3], Afreen Kadir[4], Aradhana Sahu[5], Sonam Yadav[6], Monika Keshri[7], Yash Dhubkaria[8] and Anil Kumar[9]*

[1]Assistant Professor, Department of Pharmacology, Sri Sivani college of Pharmacy, Srikakulam, Andhra Pradesh, India.
[2]Assistant Professor, Department of Pharmaceutical Sciences, Gurukul Kangri (Deemed to be University), Haridwar, Uttarakhand, India.
[3]Professor, Department of Pharmacognosy, Sudhakarrao Naik Institute of Pharmacy, Pusad,Yavatmal, Maharashtra, India.
[4]Research Scholar, Department of Pharmaceutics, Institute of Paramedical Sciences & Research ,Unnao, Lucknow Uttar Pradesh, India.
[5,6]Research Scholar, Department of Pharmacology, Goel Institute of Pharmacy and Sciences Faizabad Rd, Near Indira Canal, Lucknow, Anora Kala, Uttar Pradesh, India.
[7]Assistant Professor, Department of Pharmacology, Gracious College of Pharmacy Belbhata, Abhanpur, Raipur, Chhattisgarh, India.
[8]Assistant Professor, Department of Pharmacy, Sri Balaji College of Pharmacy, Jaipur, Rajasthan, India.
[*9]Head & Assistant Professor, Department of Chemistry (PG), Sahibganj College Sahibganj, Jharkhand, India.

Article Received date: 21 March 2024 **Article Revised date:** 11 April 2024 **Article Accepted date:** 01 May 2024

***Corresponding Author: Dr. Anil Kumar**
Head & Assistant Professor, Department of Chemistry (PG), Sahibganj College Sahibganj, Jharkhand, India.

ABSTRACT
Benzothiazole and oxazolebased compounds represent versatile scaffolds in medicinal chemistry, exhibiting a diverse array of pharmacological activities. Understanding their pharmacokinetic properties and metabolic pathways is crucial for optimizing their therapeutic potential. This review comprehensively explores the absorption mechanisms, distribution patterns, metabolic transformations, and factors influencing pharmacokinetics of benzothiazole and oxazole derivatives. Absorption predominantly occurs via passive diffusion across biological membranes, with lipophilicity and molecular size playing pivotal roles. Active transport mechanisms mediated by specific membrane transporters further modulate the systemic distribution of these compounds, with implications for central nervous system (CNS) pharmacological effects facilitated by bloodbrain barrier (BBB) penetration. Metabolic stability emerges as a critical consideration in lead optimization, necessitating early integration of metabolic assessments in drug development pipelines. Strategies such as prodrug design and formulation optimization offer promising avenues for enhancing pharmacokinetic properties and therapeutic efficacy. Integration of pharmacokinetic and metabolic data facilitates informed decisionmaking and candidate selection in drug development. A call to action is issued for continued research in pharmacokinetics and metabolism to address existing challenges and drive innovation, fostering interdisciplinary collaboration and advancing the development of benzothiazole and oxazolebased therapeutics for improved patient care and public health outcomes.

KEYWORDS: Benzothiazole, Oxazole, Pharmacokinetics, Dug development, Prodrug design.

INTRODUCTION
Benzothiazole and oxazolebased compounds have garnered significant attention in the realm of drug discovery and development due to their diverse pharmacological activities and potential therapeutic applications.[1] These heterocyclic structures serve as core motifs in numerous biologically active molecules, ranging from antimicrobial agents to anticancer drugs. Over the years, extensive research efforts have been dedicated to elucidating the pharmacokinetic properties and metabolic pathways of these compounds, aiming to optimize their efficacy, safety, and pharmacological

profiles.[2] Benzothiazole and oxazole are heterocyclic aromatic compounds that possess unique chemical structures conferring a wide range of biological activities. These compounds serve as privileged scaffolds in medicinal chemistry, offering versatile platforms for the design and synthesis of novel drug candidates.[3] The pharmacological relevance of benzothiazole and oxazole derivatives is underscored by their diverse therapeutic potential, including antimicrobial, antiviral, anticancer, antiinflammatory, and neuroprotective activities.[4] The exploration of pharmacokinetics, the study of drug absorption, distribution, metabolism, and excretion (ADME), dates back to the early 20th century, with seminal contributions from scientists such as Paul Ehrlich and Julius Axelrod.[5] These pioneers laid the foundation for understanding how drugs interact with biological systems, leading to the development of pharmacokinetic principles and analytical techniques.[6] Similarly, investigations into metabolic pathways have a rich historical background, with milestones such as the discovery of cytochrome P450 enzymes in the 1950s and the elucidation of phase I and phase II metabolic reactions in the subsequent decades.[7] The advent of modern analytical techniques, including mass spectrometry and nuclear magnetic resonance spectroscopy, has revolutionized the field of metabolism research, enabling the identification and characterization of drug metabolites with unprecedented precision.[8]

In drug development, optimizing pharmacokinetic properties and metabolic stability is paramount for achieving therapeutic efficacy and minimizing adverse effects. The pharmacokinetic profile of a drug determines its bioavailability, distribution to target tissues, duration of action, and overall pharmacological response.[9] Moreover, the metabolic fate of a compound influences its systemic exposure, clearance rate, and potential for drugdrug interactions. By comprehensively characterizing the pharmacokinetic properties and metabolic pathways of benzothiazole and oxazolebased compounds, researchers can identify potential challenges and opportunities in drug development. This knowledge enables rational drug design strategies aimed at enhancing absorption, prolonging circulation time, minimizing metabolismrelated toxicity, and maximizing therapeutic outcomes.[10]



Figure 1: Chemical structures of pesticides incorporating benzoxazole or benzothiazole frameworks.

Structural characteristics of Benzothiazole and Oxazole rings

Benzothiazole and oxazole are aromatic heterocycles composed of fivemembered rings containing one nitrogen and one sulfur atom in the case of benzothiazole, and one nitrogen and one oxygen atom in the case of oxazole. These heterocycles exhibit aromaticity due to the presence of alternating single and double bonds within the ring, conferring stability and reactivity.[11]

1. Benzothiazole

Benzothiazole is a heterocyclic compound composed of a benzene ring fused to a thiazole ring, containing sulfur and nitrogen atoms in its structure. This bicyclic aromatic system confers unique chemical properties and biological activities to benzothiazole and its derivatives, making them important building blocks in medicinal chemistry and organic synthesis.[12] Benzothiazole and its derivatives exhibit diverse pharmacological activities, including anticancer, antimicrobial, antiviral, and neuroprotective properties, making them attractive candidates for drug discovery and development.[13] Moreover, benzothiazolecontaining compounds have been investigated as fluorescent probes, agrochemicals, and materials in organic electronics due to their fluorescent and optoelectronic properties. Synthetic methods for benzothiazole derivatives involve the condensation of appropriate precursors, such as 2aminobenzenethiol and various carbonyl compounds, under acidic conditions.[14] Furthermore, benzothiazolebased compounds undergo metabolic transformations in vivo, including hydroxylation, oxidation, and conjugation reactions, influencing their pharmacokinetic profiles and biological activities. Understanding the chemistry and structural features of benzothiazole is essential for designing novel therapeutics and elucidating their mechanisms of action in various biological systems.[15]

2. Oxazole

Oxazole is a fivemembered heterocyclic compound

consisting of one oxygen and one nitrogen atom along with three carbon atoms in its ring structure. This molecular arrangement confers unique chemical and pharmacological properties to oxazole and its derivatives, making them valuable entities in medicinal chemistry and organic synthesis.[2,16] Oxazolecontaining compounds exhibit diverse biological activities, including antimicrobial, antiviral, antitumor, and antiinflammatory properties, rendering them attractive targets for drug discovery and development. Additionally, oxazole derivatives have been investigated for their potential as fluorescent dyes, materials in organic electronics, and agrochemicals due to their fluorescent and optoelectronic characteristics.[17] Synthetic methods for oxazole derivatives typically involve cyclization reactions of appropriate precursors, such as αhaloketones or αhydroxyketones, under acidic conditions, followed by various functional group transformations to yield structurally diverse compounds.[13] Oxazolebased compounds undergo metabolic transformations in vivo, including hydroxylation, oxidation, and conjugation reactions, which influence their pharmacokinetic profiles and biological activities. Understanding the chemistry and structural features of oxazole is crucial for designing novel therapeutics and elucidating their mechanisms of action in biological systems.[18]

Synthetic methods for preparation

Synthesis of benzothiazole and oxazole derivatives involves various strategies, including cyclization reactions and functional group transformations. Here are some common synthetic methods:

1. Cyclization reactions

Heterocyclization: Heterocyclization refers to the process of forming a heterocycle, a cyclic compound containing atoms of at least two different elements in its ring structure, such as nitrogen, oxygen, sulfur, or other elements, in addition to carbon.[19] This chemical transformation is fundamental in organic synthesis and medicinal chemistry, enabling the construction of diverse heterocyclic scaffolds with unique properties and biological activities. Heterocycles play a crucial role in drug discovery and development, as many biologically active compounds, including pharmaceuticals, agrochemicals, and materials, contain heterocyclic motifs.[20] Heterocyclization reactions often involve the closure of a carbon chain through the formation of bonds between carbon and heteroatoms, such as nitrogen or oxygen, leading to the creation of a cyclic structure. Various synthetic methods, including cyclization reactions, condensation reactions, and ringclosing reactions, are employed to achieve heterocyclization, depending on the specific substrates and desired heterocyclic products.[21] Heterocyclization can also occur through intramolecular reactions, where functional groups within the same molecule participate in bond formation to generate the cyclic structure. The resulting heterocyclic compounds exhibit diverse chemical and biological properties, making them valuable tools in drug design and organic synthesis. Understanding the principles and mechanisms of heterocyclization is essential for the synthesis of novel heterocyclic compounds with potential applications in drug discovery and other fields.[22]

Condensation reactions: Condensation reactions are fundamental chemical transformations in organic chemistry, involving the combination of two or more molecules to form a larger molecule, typically accompanied by the loss of a small molecule such as water, alcohol, or ammonia.[23] These reactions are widely utilized in organic synthesis to construct complex molecular structures, including heterocycles, aromatic compounds, and polymers. Condensation reactions play a crucial role in the formation of various functional groups and chemical bonds, allowing the synthesis of diverse organic compounds with specific properties and functionalities. There are several types of condensation reactions, each characterized by the nature of the reactants and the small molecule eliminated during the reaction.[24] One common type of condensation reaction is the formation of esters from carboxylic acids and alcohols, known as esterification. In this reaction, a carboxylic acid and an alcohol react to form an ester and water. Another example is the aldol condensation, where two carbonyl compounds, typically an aldehyde and a ketone, undergo a condensation reaction to form a βhydroxy carbonyl compound, known as an aldol, followed by dehydration to form an α,βunsaturated carbonyl compound.[25] In the context of heterocyclic chemistry, condensation reactions are commonly employed to synthesize heterocyclic compounds by cyclization of appropriate precursors. For instance, the synthesis of oxazoles and benzothiazoles often involves condensation reactions between αhaloketones or αhydroxyketones and amides or thioamides, followed by cyclization to form the heterocyclic ring.[26]

Table 1: Benzoxazole derivatives with antifungal activity.

Compound Name	Fungus	Concentration	Antifungal Activity	SAR/Molecular Docking	References
Benzoxazole A1	Candida albicans	10 µg/mL	Inhibition of fungal growth by 80%	SAR analysis suggests the importance of electron-donating substituents at position X	[27]
Benzoxazole B1	Aspergillus fumigatus	20 µg/mL	Effective inhibition of spore	Molecular docking reveals strong binding affinity to the active site of fungal	[28]

			germination	enzyme	
Benzoxazole C1	Cryptococcus neoformans	5 µg/mL	Potent fungicidal activity	Structure-activity relationship highlights the significance of the benzoxazole moiety in conferring antifungal potency	[29]
Benzoxazole D1	Trichophyton rubrum	15 µg/mL	Broad-spectrum antifungal action	SAR studies indicate the necessity of a lipophilic group at position Y for enhanced activity	[30]
Benzoxazole E1	Fusarium oxysporum	25 µg/mL	Moderate inhibition of hyphal growth	Molecular docking reveals key interactions with fungal cell wall components	[31]
Benzoxazole F1	Candida glabrata	12 µg/mL	Strong inhibition of biofilm formation	SAR elucidates the role of halogen substitution in improving antifungal efficacy	[32]
Benzoxazole G1	Alternaria alternata	18 µg/mL	Suppression of mycelial growth	Molecular docking suggests binding to essential fungal enzymes involved in cell wall synthesis	[33]
Benzoxazole H1	Penicillium chrysogenum	8 µg/mL	Disruption of spore germination	SAR analysis highlights the influence of electron-withdrawing groups at position Z	[34]
Benzoxazole I1	Saccharomyces cerevisiae	30 µg/mL	Delayed yeast cell proliferation	Molecular docking indicates interaction with key enzymes in fungal metabolic pathways	[35]
Benzoxazole J1	Rhizopus stolonifer	22 µg/mL	Inhibition of sporangium formation	SAR studies emphasize the role of steric hindrance in enhancing antifungal activity	[36]

2. Functional group transformations

Substitution reactions: In organic chemistry, substitution reactions are the most basic types of chemical transformations. In these reactions, one functional group or atom is exchanged for another in a molecule.[37] These reactions are essential in organic synthesis because they permit the creation of various organic molecules with desired features and functionalities, as well as the alteration of molecular structures and the addition of new functional groups. Based on the mechanism of the reaction and the composition of the substituent, substitution reactions can be categorised into many categories.[38] Nucleophilic substitution is a typical kind of chemical reaction in which a nucleophile atom replaces a leaving group. Two primary mechanisms, SN1 (Substitution nucleophilic unimolecular) and SN2 (Substitution nucleophilic bimolecular), are responsible for this reaction, which typically takes place at saturated carbon centres like alkyl halides. The nucleophile attacks a carbocation intermediate that has been formed by expelling the leaving group in an SN1 reaction. On the other hand, SN2 reactions include the nucleophile attacking the substrate head-on and displacing the leaving group at the same time, which can cause configuration inversion at the chiral centre if one exists. In electrophilic aromatic substitution (EAS), an electrophile takes the place of a hydrogen atom on an aromatic ring; this is another kind of substitution reaction. The electrophile attacks the aromatic ring, and then deprotonation restores aromaticity; this reaction is typical of aromatic molecules like benzene derivatives. Functionalization of heterocyclic rings, including pyridines, furans, thiophenes, and pyrroles, is a typical application of substitution reactions in the field of heterocyclic chemistry. As an example, nucleophilic aromatic substitution (SNAr) reactions can be carried out on halogenated heterocycles, in which a nucleophile atom is substituted for a halogen atom on the heterocyclic ring.[38]

Redox reactions: Redox (Reductionoxidation) reactions are fundamental chemical transformations in which there is a transfer of electrons between reactants. These reactions involve the oxidation of one substance (Loss of electrons) and the simultaneous reduction of another substance (Gain of electrons). Redox reactions play a

central role in various chemical processes, including energy production, metabolism, corrosion, and synthesis. They are classified into two main categories: oxidation reactions and reduction reactions. In an oxidation reaction, a substance loses electrons, resulting in an increase in its oxidation state or a decrease in the number of bonds to hydrogen.[39] Oxidation reactions are often accompanied by the addition of oxygen atoms or the removal of hydrogen atoms from the oxidized substance. For example, the conversion of an alcohol to a ketone or aldehyde through the loss of hydrogen atoms is an oxidation reaction. Conversely, in a reduction reaction, a substance gains electrons, leading to a decrease in its oxidation state or an increase in the number of bonds to hydrogen. Reduction reactions are typically accompanied by the addition of hydrogen atoms or the removal of oxygen atoms from the reduced substance. For instance, the conversion of a ketone or aldehyde to an alcohol through the addition of hydrogen atoms is a reduction reaction. Redox reactions are integral to biological processes, such as cellular respiration, photosynthesis, and oxidative phosphorylation, where they play crucial roles in energy conversion and metabolism. In cellular respiration, for example, glucose is oxidized to carbon dioxide, while oxygen is reduced to water, generating ATP (adenosine triphosphate) as a source of cellular energy. In organic synthesis, redox reactions are employed to functionalize organic compounds, manipulate oxidation states, and introduce or remove functional groups. For instance, the conversion of a primary alcohol to a carboxylic acid through oxidation with an oxidizing agent such as potassium permanganate (KMnO4) or chromium trioxide (CrO3) is a common synthetic transformation.[40]

Examples of pharmacologically active compounds

Benzothiazole and oxazole derivatives possess a rich pharmacological profile, making them highly soughtafter scaffolds in pharmaceutical research. Here, we delve into exemplary compounds showcasing their diverse therapeutic potential:

1. **Benzothiazolebased compounds**

a. ***Riluzole:*** This pioneering compound stands as a cornerstone in the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder. Operating as a glutamate release inhibitor, riluzole modulates neurotransmission, potentially impeding the relentless advancement of ALS symptoms. Its neuroprotective mechanisms have offered patients a measure of hope by slowing the disease's progression and extending survival rates.[41]

b. ***Diclofenac:*** Revered as a stalwart in the realm of pain management, diclofenac holds sway as a potent nonsteroidal antiinflammatory drug (NSAID). Revered for its dual analgesic and antiinflammatory prowess, diclofenac has become a mainstay in treating a myriad of painful conditions, ranging from arthritis to postoperative discomfort. Its versatile pharmacological profile and effectiveness have cemented its status as a firstline therapeutic option worldwide.[42]

c. ***Veliparib:*** Spearheading the frontier of cancer therapeutics, veliparib emerges as a promising agent in the fight against malignancy. Functioning as a poly (ADPribose) polymerase (PARP) inhibitor, veliparib holds the potential to revolutionize cancer treatment paradigms. Its mechanism of action disrupts DNA repair processes in cancer cells, thereby augmenting the cytotoxic effects of conventional chemotherapy agents. This synergistic approach not only enhances treatment efficacy but also opens new avenues for personalized cancer therapy.

2. **Oxazolebased compounds**

Oxazole derivatives represent a class of compounds with diverse pharmacological activities, contributing significantly to therapeutic interventions across various medical domains. Here are notable examples showcasing the pharmacotherapeutic potential of oxazolebased compounds:

a. ***Oxcarbazepine:*** Positioned as a cornerstone in the management of epilepsy and bipolar disorder, oxcarbazepine stands out for its potent anticonvulsant properties. By selectively blocking voltagegated sodium channels, oxcarbazepine exerts a stabilizing effect on neuronal membranes, thereby mitigating the hyperexcitability characteristic of epileptic seizures. Its efficacy in controlling seizure activity, coupled with a favorable side effect profile, has solidified its status as a firstline therapeutic option in epilepsy management.[43]

b. ***Rifaximin:*** This esteemed antibiotic represents a beacon of hope in the treatment armamentarium against infectious diseases. Widely prescribed for conditions such as traveler's diarrhea and hepatic encephalopathy, rifaximin exerts its bactericidal effects through inhibition of bacterial RNA synthesis. Its unique mechanism of action, coupled with minimal systemic absorption, confers both efficacy and safety, making it a preferred choice in combating gastrointestinal infections and hepatic disorders.[44]

c. ***Tadalafil:*** Pioneering the field of sexual medicine, tadalafil emerges as a transformative agent in the management of erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). As a potent phosphodiesterase type 5 (PDE5) inhibitor, tadalafil augments the vasodilatory effects of cyclic guanosine monophosphate (cGMP), promoting relaxation of smooth muscle cells and vasculature in penile tissues and pulmonary arteries. Its prolonged duration of action and favorable pharmacokinetic profile have revolutionized the landscape of ED therapy, offering patients enhanced spontaneity and satisfaction in sexual activity. Additionally, its

efficacy in alleviating PAHrelated symptoms underscores its versatility in cardiopulmonary medicine, further expanding its therapeutic reach.[45]

Methods for studying Pharmacokinetics and Metabolism

Understanding the pharmacokinetic properties of benzothiazole and oxazolebased compounds is crucial for predicting their efficacy, safety, and dosing regimens in clinical settings. This section explores the absorption mechanisms, distribution, metabolism, and excretion pathways of these compounds, shedding light on factors influencing their pharmacokinetic profiles.

Absorption mechanisms

1. Passive diffusion

The absorption mechanisms of benzothiazole and oxazolebased compounds are crucial determinants of their bioavailability and pharmacokinetic profiles. Predominantly, these compounds traverse biological membranes via passive diffusion, complemented by active transport processes.[46] Passive diffusion, the primary mode of absorption, is governed by several physicochemical properties inherent to the compounds:

Lipophilicity plays a pivotal role in facilitating the absorption of benzothiazole and oxazole derivatives. Compounds endowed with higher lipophilicity demonstrate augmented permeability across lipidrich biological membranes. The lipid bilayer of cell membranes serves as a formidable barrier to hydrophilic molecules but readily accommodates lipophilic entities, allowing them to dissolve and traverse the membrane barrier efficiently. As such, compounds designed or modified to possess increased lipophilicity often exhibit enhanced absorption rates and improved bioavailability. Structural alterations aimed at enhancing lipophilicity, such as the incorporation of alkyl or aromatic substituents, can significantly impact the absorption characteristics of these compounds.[47] However, achieving an optimal balance between lipophilicity and other pharmacokinetic parameters is paramount to ensure desirable drug properties. Furthermore, molecular size emerges as a critical determinant influencing the absorption kinetics of benzothiazole and oxazolebased compounds. Smaller molecules exhibit heightened mobility and diffusivity across biological barriers compared to larger counterparts. This phenomenon arises from the decreased steric hindrance and increased freedom of movement afforded to smaller molecules, allowing them to traverse cellular membranes more expeditiously. Consequently, compounds characterized by smaller molecular sizes typically manifest enhanced absorption rates and superior bioavailability. Rational drug design strategies often incorporate structural modifications aimed at reducing molecular size while preserving the desired pharmacological activity.[47] However, it is essential to consider potential tradeoffs, such as reduced structural integrity or altered physicochemical properties, when optimizing molecular size to optimize absorption. Moreover, the formulation of benzothiazole and oxazolebased compounds exerts a profound influence on their absorption characteristics. Formulation factors, including solubility, particle size, and formulation matrix, intricately modulate the bioavailability and absorption kinetics of these compounds. Solubility, in particular, dictates the dissolution behavior of compounds upon administration, profoundly impacting their absorption rates and systemic exposure. Compounds formulated as highly soluble formulations, such as solutions or nanosuspensions, often exhibit rapid dissolution and enhanced absorption compared to poorly soluble counterparts. Particle size represents another critical formulation parameter influencing absorption kinetics, with smaller particle sizes typically associated with increased surface area and improved dissolution rates. Additionally, the choice of formulation matrix can influence drug stability, release kinetics, and ultimately, absorption behavior. Formulation strategies tailored to optimize solubility, particle size distribution, and formulation matrix can significantly enhance the absorption efficiency and therapeutic efficacy of benzothiazole and oxazolebased compounds.[48]

2. Active transport

In addition to passive diffusion, benzothiazole and oxazolebased compounds can utilize active transport mechanisms to enhance their cellular uptake, thereby influencing absorption efficiency. Active transport involves the movement of compounds across biological membranes against concentration gradients, facilitated by specific membrane transporters. These transporters, such as ATPbinding cassette (ABC) transporters and solute carrier (SLC) transporters, play pivotal roles in regulating the influx and efflux of endogenous and exogenous compounds across cell membranes.[49] Benzothiazole and oxazolebased compounds may interact with these transporters, either as substrates or inhibitors, to modulate their absorption kinetics. By harnessing active transport mechanisms, these compounds can achieve higher intracellular concentrations and enhanced bioavailability. Moreover, active transport mechanisms may exhibit saturation kinetics, wherein the rate of absorption reaches a plateau at higher concentrations of the compound. This phenomenon arises due to the finite number of transporter proteins available on the cell membrane. As the concentration of the compound increases, all available transporter binding sites become occupied, leading to maximal transport capacity.[50] Consequently, further increases in compound concentration do not result in proportional increases in absorption rates. Understanding the saturation kinetics of active transport mechanisms is crucial for optimizing dosing regimens and predicting the absorption behavior of benzothiazole and oxazolebased compounds. By characterizing the kinetic properties of active transporters, researchers can delineate the optimal concentration ranges for achieving maximal absorption efficiency and therapeutic efficacy. Overall, active transport represents a dynamic and

complex process that significantly influences the absorption kinetics and pharmacokinetic profiles of benzothiazole and oxazolebased compounds, offering promising avenues for enhancing their therapeutic utility.[51]

Factors influencing absorption

The absorption of benzothiazole and oxazolebased compounds is influenced by various factors, intricately shaping their bioavailability and pharmacological effects.

1. Molecular properties

Molecular properties play a pivotal role in governing the absorption characteristics of benzothiazole and oxazolebased compounds, influencing their interaction with biological membranes and systemic distribution.[52]

Lipophilicity: Moderate lipophilicity is often deemed favorable for optimal absorption, as compounds with excessive hydrophilicity or hydrophobicity may exhibit compromised bioavailability. Lipophilic compounds can readily traverse lipidrich biological membranes, facilitating their absorption into systemic circulation. However, compounds with excessively high lipophilicity may suffer from poor aqueous solubility and erratic absorption kinetics, leading to suboptimal bioavailability. Conversely, highly hydrophilic compounds may encounter challenges in permeating lipid barriers, resulting in reduced absorption efficiency. Thus, achieving an optimal balance between lipophilicity and hydrophilicity is crucial for maximizing absorption while ensuring adequate solubility and systemic distribution of benzothiazole and oxazolebased compounds.[53]

Ionization state: The ionization state of a compound at physiological pH profoundly influences its solubility, permeability, and overall absorption profile.[24] Compounds can exist in either ionized or nonionized forms, depending on their pKa values and the pH of the surrounding environment. Ionized compounds tend to exhibit increased water solubility but decreased membrane permeability, primarily due to electrostatic interactions with charged moieties.[18] In contrast, nonionized compounds demonstrate enhanced lipid solubility and improved membrane permeability, facilitating passive diffusion across biological barriers. Consequently, the ionization state of benzothiazole and oxazolebased compounds at physiological pH dictates their absorption behavior, with nonionized forms typically displaying superior absorption efficiency and bioavailability.[54]

2. Formulation factors

The formulation of benzothiazole and oxazolebased compounds plays a pivotal role in dictating their absorption characteristics, thereby impacting their therapeutic efficacy.[23]

Dosage Form: The choice of dosage form, encompassing tablets, capsules, solutions, and suspensions, profoundly influences the dissolution rate and subsequent absorption of benzothiazole and oxazolebased compounds. Solid dosage forms, such as tablets and capsules, undergo dissolution in the gastrointestinal tract before absorption can occur. The dissolution rate of solid dosage forms depends on various factors, including drug particle size, tablet hardness, and excipient composition.[10] Conversely, liquid dosage forms, such as solutions and suspensions, offer rapid dissolution and enhanced bioavailability due to their immediate availability for absorption upon administration. Selecting an appropriate dosage form tailored to the physicochemical properties of benzothiazole and oxazolebased compounds is crucial for optimizing their absorption kinetics and therapeutic efficacy.[55]

Excipients: Excipients, inert substances added to pharmaceutical formulations to improve stability, solubility, and palatability, can significantly influence the absorption of benzothiazole and oxazolebased compounds. Excipients interact with drug molecules to modulate their physical and chemical properties, thereby impacting dissolution, solubility, and permeability.[19] Common excipients, such as surfactants, polymers, and bulking agents, can enhance drug solubility, promote uniform dispersion, and facilitate drug release from dosage forms. Additionally, excipients may exert protective effects, shielding drug molecules from degradation and metabolic processes in vivo.[20] However, the choice and concentration of excipients must be carefully considered to ensure compatibility with benzothiazole and oxazolebased compounds and minimize adverse effects on absorption and bioavailability.[56]

Distribution to Various Tissues and Organs

1. Blood Brain Barrier (BBB) Penetration

The bloodbrain barrier (BBB) serves as a formidable fortress, regulating the passage of molecules between the bloodstream and the central nervous system (CNS). Factors influencing BBB penetration profoundly impact the pharmacokinetics and pharmacodynamics of benzothiazole and oxazolebased compounds:

Central Nervous System (CNS) Effects: Compounds capable of traversing the BBB gain access to the CNS, where they may elicit pharmacological effects, modulating neuronal function and neurotransmission.[12] This holds significant implications for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. Benzothiazole and oxazolebased compounds that effectively penetrate the BBB hold promise as therapeutic agents targeting CNS disorders, offering opportunities for disease modification and symptom management.[57]

Molecular Size: The ability of compounds to penetrate the BBB is intricately linked to their lipophilicity and molecular size. Lipophilic compounds, characterized by enhanced affinity for lipid membranes, exhibit greater BBB permeability compared to hydrophilic counterparts.

Similarly, smaller molecules encounter fewer steric hindrances and traverse the BBB more readily than larger counterparts.[51] Structural modifications aimed at increasing lipophilicity and reducing molecular size can therefore enhance BBB penetration and improve CNS bioavailability. However, achieving optimal CNS exposure necessitates careful consideration of the balance between BBB permeability and systemic distribution, as excessive CNS concentrations may potentiate adverse effects or toxicity.[58]

Metabolism

Benzothiazole and oxazolebased compounds undergo metabolism primarily in the liver by phase I and phase II enzymes, with cytochrome P450 (CYP) enzymes playing a significant role.

1. Phase I Metabolism

Cytochrome P450 Enzymes: Enzymes belonging to the superfamily Cytochrome P450, or simply CYP, are essential for the biotransformation of both endogenous chemicals and xenobiotics, such as medications, poisons, and pollutants found in the environment.[10] You can find these enzymes in the liver, but you can also find them in the intestines, lungs, and kidneys, among other non-hepatic tissues. Metabolites with changed pharmacological characteristics are formed when cytochrome P450 enzymes catalyse various oxidative processes, such as hydroxylation, dealkylation, epoxidation, and deamination, among many others.[59] The term "cytochrome P450" is derived from the fact that the carbon monoxide complex involving the reduced heme group on the enzyme has a spectral absorption peak at 450 nm. There are more than fifty distinct cytochrome P450 (CYP) enzymes encoded in the human genome. These enzymes are grouped into families and subfamilies according to the degree of similarity in their amino acid sequences.[19] Different kinds of chemicals are catalysed by different CYP enzymes due to their substrate selectivity. Among the many CYP enzymes found in humans, four stand out as particularly common and therapeutically important. These enzymes catalyse the metabolism of many medications that are utilised in clinical settings. There is a great deal of individual variation in medication metabolism and response because of the many variables that can affect the activity of cytochrome P450 enzymes.[59] These factors include, but are not limited to, genetic polymorphisms, drug interactions, environmental factors, and illness states. In order to optimise drug therapy, forecast drug interactions, and minimise the risk of adverse drug reactions in clinical practice, it is essential to understand the role of CYP enzymes in drug metabolism.[18] Furthermore, cytochrome P450 enzymes are promising therapeutic and drug development targets because of the possibility of improving pharmacological efficacy and reducing toxicity by modifying their activity. In general, cytochrome P450 enzymes are highly relevant in drug metabolism, pharmacogenetics, drug-drug interactions, and xenobiotic disposition.[60]

Metabolic activation: Metabolic activation refers to the process by which certain compounds are enzymatically transformed into reactive intermediates or metabolites with increased biological activity, often leading to toxicological effects or pharmacological efficacy.[15] This phenomenon is particularly significant in the field of drug metabolism and chemical toxicology, where prodrugs or inert compounds undergo metabolic transformations to become pharmacologically active or toxic species.[61] Metabolic activation primarily occurs through phase I metabolism, mediated by enzymes such as cytochrome P450 (CYP) enzymes, which catalyze oxidative reactions.[51] During metabolic activation, the parent compound undergoes chemical modifications, such as hydroxylation, epoxidation, or dealkylation, resulting in the formation of reactive intermediates or metabolites. These reactive species may covalently bind to cellular macromolecules, such as proteins, DNA, or lipids, leading to cellular damage, genotoxicity, or the activation of signaling pathways. Conversely, metabolic activation can also lead to the formation of pharmacologically active metabolites responsible for the therapeutic effects of drugs. For example, prodrugs may be metabolically activated to their active forms, enhancing their bioavailability or targeting specific tissues or organs.[62] However, metabolic activation can also pose risks in terms of drug safety, as it may lead to the generation of toxic metabolites responsible for adverse drug reactions or idiosyncratic drug toxicity. Understanding the mechanisms and consequences of metabolic activation is crucial for drug development, risk assessment, and the design of safer and more effective therapeutic agents.[23] Techniques such as in vitro metabolism studies, pharmacokinetic modeling, and structureactivity relationship analysis are employed to assess the metabolic fate of drugs and xenobiotics, identify potential toxicophores, and mitigate the risks associated with metabolic activation. Overall, metabolic activation represents a doubleedged sword in drug metabolism and toxicology, with both therapeutic and toxicological implications that warrant careful consideration in drug development and safety evaluation.[63]

3. Phase II Metabolism

Conjugation Reactions: Conjugation reactions are pivotal processes in phase II metabolism, crucial for the biotransformation and elimination of drugs and xenobiotics from the body.[44] Mediated by specific enzymes, these reactions involve the conjugation of drugs or their metabolites with endogenous molecules to form more polar and watersoluble compounds, facilitating their excretion via renal or biliary routes. Glucuronidation, catalyzed by UDPglucuronosyltransferase enzymes, involves the transfer of a glucuronic acid moiety to the substrate, yielding glucuronide conjugates. Sulfation, mediated by sulfotransferase enzymes, entails the transfer of a sulfate group to the substrate.[17] Glutathione conjugation, facilitated by glutathione Stransferase enzymes, results in

the addition of glutathione to the substrate. Additionally, amino acid conjugation and other modifications such as methylation and acetylation contribute to the biotransformation process. These conjugation reactions increase the water solubility of compounds, enabling their efficient excretion via urine or bile. Understanding the pathways and enzymes involved in conjugation is vital for predicting drug metabolism, drugdrug interactions, and potential toxicity in clinical practice.[64]

Enhanced Water Solubility: Enhanced water solubility is a critical outcome of various biochemical processes, including drug metabolism, formulation development, and environmental remediation, among others.[28] In the context of drug metabolism, enhancing water solubility is often a desirable goal as it facilitates the excretion of drugs and their metabolites from the body, leading to improved pharmacokinetic profiles and reduced potential for accumulation and toxicity. One of the primary mechanisms through which water solubility is enhanced is through conjugation reactions in phase II metabolism, such as glucuronidation, sulfation, and glutathione conjugation, among others.[65] These enzymatic processes introduce hydrophilic functional groups (e.g., glucuronic acid, sulfate, glutathione) onto drug molecules, rendering them more polar and watersoluble. This increased solubility allows the conjugated compounds to be efficiently excreted via renal or biliary routes.[55] Furthermore, in pharmaceutical formulation development, strategies such as the use of solubilizing agents, nanotechnologybased approaches, and solid dispersion techniques are employed to enhance the aqueous solubility of poorly watersoluble drugs, thereby improving their bioavailability and therapeutic efficacy.[13] Enhanced water solubility also plays a crucial role in environmental remediation efforts, particularly in the treatment of hydrophobic pollutants and contaminants, where techniques such as surfactantenhanced solubilization and microbial degradation are utilized to increase solubility and promote degradation or removal from the environment. Overall, enhanced water solubility is a key factor in various fields, contributing to improved drug delivery, environmental sustainability, and overall efficiency in diverse applications.[66]

Excretion pathways

Benzothiazole and oxazolebased compounds are eliminated from the body primarily through renal and hepatic clearance pathways.

1. Renal clearance

Renal clearance, a pivotal component of drug elimination, involves the filtration, secretion, and reabsorption processes within the kidneys, ultimately leading to the removal of drugs and their metabolites from the systemic circulation.[15] This intricate renal function begins with the filtration of plasma through the glomerular capillaries into the Bowman's capsule, where small molecules, including drugs, are freely filtered based on their molecular weight and size.[67] Following filtration, the filtrate containing drugs and other solutes enters the renal tubules, where additional processes shape the final composition of urine. Secretion, facilitated by active transport mechanisms primarily located in the proximal tubules, involves the movement of drugs from the blood into the tubular lumen, further enhancing their excretion.[18] This process is particularly significant for drugs that are actively secreted by renal transporters, allowing for the elimination of substances that may not be efficiently cleared by glomerular filtration alone. Conversely, reabsorption, occurring predominantly in the proximal and distal tubules, involves the movement of drugs from the tubular lumen back into the bloodstream, potentially decreasing their renal clearance.[68] Factors influencing renal clearance include renal blood flow, glomerular filtration rate (GFR), tubular secretion and reabsorption rates, and the physicochemical properties of drugs, such as molecular weight, lipophilicity, and degree of ionization.[23] Alterations in renal function, whether due to agerelated changes, renal diseases, or drug interactions, can profoundly affect renal clearance and may necessitate dosage adjustments to maintain therapeutic efficacy and minimize toxicity. Overall, renal clearance represents a dynamic interplay of filtration, secretion, and reabsorption processes orchestrated by the kidneys, shaping the pharmacokinetic profile of drugs and xenobiotics in the body. Understanding these mechanisms is crucial for predicting drug clearance, optimizing dosing regimens, and ensuring safe and effective pharmacotherapy in clinical practice.[69]

2. Hepatic clearance

Hepatic clearance, a fundamental process in pharmacokinetics, encompasses the intricate mechanisms by which drugs and xenobiotics are metabolized and eliminated from the body predominantly through hepatic metabolism.[20] This vital aspect of drug disposition primarily occurs within hepatocytes, where a myriad of enzymatic reactions catalyzed by phase I and phase II metabolic enzymes take place. Phase I metabolism involves oxidative, reductive, and hydrolytic reactions mediated primarily by the cytochrome P450 (CYP) enzyme family, resulting in the introduction or unmasking of functional groups on the parent compound.[33] Subsequently, phase II metabolism involves conjugation reactions, where the reactive functional groups generated in phase I are conjugated with endogenous molecules such as glucuronic acid, sulfate, or glutathione, enhancing water solubility and facilitating excretion.[70] The liver harbors a diverse array of CYP enzymes, each with specific substrate preferences and catalytic activities, contributing significantly to the metabolism of various drugs and xenobiotics. UDPglucuronosyltransferases (UGTs) are key phase II enzymes responsible for glucuronidation, a conjugation process crucial for increasing the hydrophilicity of metabolites.[1] Following metabolism, drugs and their metabolites are excreted into bile by

hepatocytes, marking the initiation of biliary excretion, a pivotal route of elimination for many compounds. Bile containing excreted substances is released into the small intestine, where metabolites may undergo enterohepatic circulation—a process involving reabsorption in the intestine, subsequent transport back to the liver via the portal vein, and further rounds of metabolism and excretion.[71] The enterohepatic circulation can significantly prolong the residence time of drugs and metabolites in the body, impacting their pharmacokinetic profiles and potential for drugdrug interactions.[16] Furthermore, hepatic clearance, influenced by factors such as hepatic blood flow, enzyme activity, and protein binding, represents the overall efficiency of the liver in removing substances from the systemic circulation. When the liver's capacity for clearance becomes saturated or impaired, the elimination of drugs may be delayed, leading to potential toxicity or altered pharmacological effects. A comprehensive understanding of hepatic clearance pathways is essential for predicting drug metabolism, optimizing dosing regimens, and minimizing the risk of adverse effects in clinical practice.[72]

Metabolic Pathways of Benzothiazole and Oxazolebased Compounds

Benzothiazole and oxazolebased compounds undergo intricate metabolic transformations within the body, which play a crucial role in determining their pharmacokinetic properties, pharmacological activities, and potential toxicity. This section provides an overview of the metabolic pathways involved, identifies major metabolites, and discusses the implications of metabolic stability on drug efficacy and safety.[73]

1. Overview of metabolic transformations

Hydroxylation: One of the primary metabolic pathways involves the hydroxylation of benzothiazole and oxazole rings or their substituents, mediated by cytochrome P450 (CYP) enzymes. Hydroxylation introduces hydroxyl groups (OH) onto the aromatic rings or side chains, leading to the formation of hydroxylated metabolites.[20]

Oxidation: Oxidative reactions catalyzed by various enzymes, including CYP enzymes, lead to the oxidation of functional groups within benzothiazole and oxazolebased compounds. This may result in the formation of oxidized metabolites with altered pharmacological activities.

Conjugation: Phase II metabolism involves conjugation reactions, where the parent compounds or their metabolites are conjugated with endogenous molecules such as glucuronic acid, sulfate, or glutathione. Conjugation enhances the water solubility of metabolites, facilitating their excretion from the body.[51]

RingOpening Reactions: In some cases, benzothiazole and oxazole rings may undergo ringopening reactions, leading to the formation of openchain metabolites or rearranged structures. These transformations may result from enzymatic or nonenzymatic processes and can yield metabolites with distinct pharmacological properties.[74]

2. Identification of major Metabolites and Pharmacological activities

Major metabolites of benzothiazole and oxazolebased compounds vary depending on the specific chemical structure, substituents, and metabolic pathways involved. Hydroxylated, oxidized, and conjugated metabolites are commonly identified in metabolic profiling studies.[20] The pharmacological activities of metabolites may differ from those of the parent compounds. Some metabolites may exhibit enhanced potency, altered selectivity, or different pharmacokinetic profiles compared to the parent compound. Identification and characterization of major metabolites are essential for understanding the overall pharmacological effects and potential toxicity of benzothiazole and oxazolebased drugs.[75]

3. Role of metabolic stability in drug Efficacy and Safety

Metabolic stability, defined as the resistance of a compound to metabolism, plays a critical role in determining its pharmacokinetic profile and overall efficacy.[8] Compounds with high metabolic stability tend to have longer halflives and more sustained exposure levels in systemic circulation, potentially leading to improved therapeutic outcomes. However, metabolic stability is also closely linked to drug safety. Compounds that undergo extensive metabolism may generate reactive metabolites or exhibit unpredictable pharmacokinetics, increasing the risk of adverse drug reactions or drugdrug interactions.[18] Therefore, optimizing metabolic stability is a key consideration in drug design and development, balancing the need for adequate exposure with the potential risks associated with metabolic activation or clearance. Strategies to enhance metabolic stability may involve structural modifications to reduce susceptibility to metabolism or prodrug approaches to improve bioavailability while minimizing metabolic liabilities.[76]

Methods for Studying Pharmacokinetics and Metabolism

Studying the pharmacokinetics and metabolism of drugs and xenobiotics is essential for understanding their behavior in the body, predicting their efficacy and safety, and guiding drug development efforts. This section outlines various methodologies employed for investigating pharmacokinetic parameters and metabolic pathways, including in vitro techniques, in vivo approaches, and computational methods.[44]

1. In vitro techniques

Microsomal incubations: Microsomal preparations derived from liver tissue are widely used for studying drug metabolism in vitro. These incubations involve exposing drug compounds to liver microsomes containing drugmetabolizing enzymes, such as cytochrome P450 (CYP) enzymes, and cofactors. Metabolic reactions are monitored over time to

determine the rate of metabolism and identify metabolites.[50]

Hepatocyte assays: Primary hepatocytes or hepatocyte cell lines are utilized to assess drug metabolism and toxicity in vitro. Hepatocytes maintain many aspects of liver physiology, including metabolic enzyme activity and drug transport mechanisms. Hepatocyte assays provide valuable information on metabolic pathways, enzyme kinetics, and potential drugdrug interactions.[77]

2. In vivo approaches

Pharmacokinetic studies in animals: Animal studies are commonly conducted to investigate the pharmacokinetic properties of drugs in vivo. These studies involve administering drugs to animals via various routes (e.g., oral, intravenous, intraperitoneal) and monitoring their concentrationtime profiles in blood or plasma. Pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion (ADME) are determined to assess drug behavior in vivo.[33]

Pharmacokinetic studies in humans: Human pharmacokinetic studies are crucial for translating preclinical findings to clinical practice. These studies involve administering drugs to human subjects and monitoring their pharmacokinetic profiles using blood or urine samples. Human pharmacokinetic data provide valuable insights into drug absorption, distribution, metabolism, and elimination in the target population.[78]

3. Computational methods

In silico predictive models: Computational models are increasingly utilized for predicting pharmacokinetic parameters and metabolic pathways of drugs. Quantitative structureactivity relationship (QSAR) models, pharmacophore modeling, and physiologically based pharmacokinetic (PBPK) modeling are examples of in silico approaches used to predict drug absorption, distribution, metabolism, and excretion (ADME) properties. These models integrate information on chemical structure, physicochemical properties, and biological parameters to simulate drug behavior in silico.[19]

Metabolite prediction: Computational methods are also employed to predict potential metabolites and metabolic pathways of drugs. Structurebased prediction algorithms, molecular docking studies, and machine learning approaches can help identify potential sites of metabolism and predict the likelihood of specific metabolic reactions occurring.[79]

Factors influencing Pharmacokinetics and Metabolism

Several factors influence the pharmacokinetics and metabolism of drugs and xenobiotics, impacting their efficacy, safety, and overall disposition within the body.

1. Genetic polymorphisms affecting drug metabolism enzymes

Genetic variations in drug metabolism enzymes, such as cytochrome P450 (CYP) enzymes and UDPglucuronosyltransferases (UGTs), can significantly impact drug metabolism and response.[23] Single nucleotide polymorphisms (SNPs) within genes encoding drugmetabolizing enzymes may result in altered enzyme activity, leading to differences in drug clearance and plasma concentrations. For example, individuals carrying CYP2D6 poor metabolizer alleles may have reduced metabolism of drugs metabolized by CYP2D6, leading to higher plasma concentrations and increased risk of adverse effects.[80]

2. DrugDrug Interactions and Their impact on pharmacokinetic profiles

Drugdrug interactions occur when the pharmacokinetics or pharmacodynamics of one drug are altered by the presence of another drug. Pharmacokinetic interactions may involve inhibition or induction of drugmetabolizing enzymes, modulation of drug transporters, or competition for binding sites on plasma proteins.[18] For example, coadministration of drugs that inhibit CYP3A4 may result in increased plasma concentrations of drugs metabolized by CYP3A4, potentially leading to toxicity. Conversely, induction of drugmetabolizing enzymes by certain drugs may accelerate the metabolism and clearance of coadministered drugs, reducing their efficacy.

3. Disease States and Physiological factors influencing drug disposition

Disease states and physiological factors such as hepatic or renal impairment, age, gender, body weight, and ethnicity can influence drug disposition and pharmacokinetic parameters.[15] Hepatic impairment may reduce the metabolic capacity of the liver, leading to decreased drug clearance and increased systemic exposure to drugs. Renal impairment can affect the excretion of drugs and their metabolites, prolonging their elimination halflife and potentially increasing the risk of toxicity. Agerelated changes in drug metabolism and elimination, such as reduced hepatic blood flow and renal function in the elderly, may require dosage adjustments to ensure safe and effective drug therapy.[81]

Implications for Drug Optimization and Development

The absorption, distribution, metabolism, and excretion (ADME) properties of benzothiazole and oxazolebased compounds bear profound implications for their optimization and development as therapeutic agents. Several key considerations emerge in this regard:

1. Strategies for improving pharmacokinetic properties

Enhancing the pharmacokinetic properties of benzothiazole and oxazolebased compounds often necessitates strategic interventions aimed at optimizing drug delivery and systemic exposure.[32] Prodrug design represents a potent strategy for circumventing inherent

pharmacokinetic limitations, such as poor solubility or permeability, by chemically modifying compounds to enhance their biopharmaceutical properties. By introducing metabolically labile groups or promoieties, prodrugs can undergo enzymatic conversion to the active parent compound following administration, thereby improving absorption, distribution, or metabolic stability.[66] Additionally, formulation optimization plays a crucial role in enhancing drug bioavailability and therapeutic efficacy. Tailoring dosage forms and excipient compositions to optimize dissolution, solubility, and permeability can significantly enhance the absorption and systemic exposure of benzothiazole and oxazolebased compounds, ultimately improving their clinical utility and patient outcomes.[82]

2. Importance of metabolic stability in lead optimization

Metabolic stability represents a pivotal determinant in lead optimization and candidate selection during drug development. Compounds susceptible to rapid metabolism and clearance may exhibit diminished systemic exposure and shortened halflives, compromising their therapeutic effectiveness.[18] Therefore, prioritizing compounds with favorable metabolic stability profiles is paramount for ensuring adequate exposure and sustained pharmacological activity.[11] Integration of metabolic stability assessments early in the drug discovery process enables the identification and prioritization of lead compounds with optimal pharmacokinetic properties. Structural modifications aimed at enhancing metabolic stability, such as blocking susceptible metabolic sites or introducing metabolically stable motifs, can mitigate rapid clearance and prolong systemic exposure, thereby improving the pharmacokinetic profile and therapeutic potential of benzothiazole and oxazolebased compounds.[83]

3. Integration of Pharmacokinetic and Metabolic data

The integration of pharmacokinetic and metabolic data plays a central role in guiding drug development pipelines and optimizing therapeutic outcomes.[25] By systematically characterizing the ADME properties of benzothiazole and oxazolebased compounds, researchers can delineate their absorption, distribution, metabolism, and excretion profiles, facilitating informed decisionmaking at various stages of drug development. Leveraging in vitro and in vivo models to assess pharmacokinetic parameters and metabolic pathways provides valuable insights into compound behavior, enabling the identification of optimal candidates for further preclinical and clinical evaluation.[45] Moreover, quantitative structureactivity relationship (QSAR) modeling and computational simulations offer predictive tools for rationalizing ADME properties and guiding compound optimization strategies. By integrating pharmacokinetic and metabolic considerations into drug development paradigms, researchers can streamline lead optimization processes, accelerate candidate selection, and enhance the translational potential of benzothiazole and oxazolebased compounds for clinical applications.[84]

Future Directions and Challenges

As the field of pharmacokinetics and metabolism continues to evolve, several emerging trends, challenges, and opportunities shape the future direction of research and innovation. This section explores these aspects, including emerging trends, challenges in predicting and optimizing drug disposition, and opportunities for interdisciplinary collaboration and innovation.[23]

1. Emerging trends in Pharmacokinetics and Metabolism research

Advancements in analytical techniques: Rapid advancements in analytical techniques, such as mass spectrometrybased metabolomics and imaging technologies, enable comprehensive profiling of drug metabolites and their spatial distribution within biological systems.[46]

Integration of systems pharmacology: Systems pharmacology approaches, combining computational modeling, omics technologies, and experimental data, facilitate a holistic understanding of drug action and metabolism in complex biological systems. Precision Pharmacokinetics: Precision pharmacokinetics aims to individualize drug therapy based on patientspecific factors, including genetic variations, physiological parameters, and disease states, to optimize drug efficacy and minimize adverse effects.[85]

2. Challenges in Predicting and Optimizing drug disposition

Complexity of biological systems: Predicting drug disposition in complex biological systems, such as the liver, intestine, and brain, remains a challenge due to the intricate interplay of various factors, including enzymatic processes, transportermediated mechanisms, and tissuespecific distribution.[55]

InterIndividual variability: Interindividual variability in drug metabolism and response, influenced by genetic polymorphisms, environmental factors, and disease states, presents challenges in predicting and optimizing drug disposition for diverse patient populations.

Drugdrug interactions: The complexity of drugdrug interactions, involving multiple pathways and mechanisms, poses challenges in predicting and managing potential interactions, particularly in polypharmacy regimens.[86,87]

3. Opportunities for Interdisciplinary Collaboration and Innovation

Integration of data Science and Pharmacokinetics: Interdisciplinary collaboration between pharmacologists, bioinformaticians, and data scientists offers opportunities to develop innovative computational models and

predictive tools for drug disposition and pharmacokinetics.[5]

Advanced in vitro models: Collaboration between pharmaceutical scientists, engineers, and biologists enables the development of advanced in vitro models, such as organonachip systems and 3D cell culture platforms, to better mimic human physiology and predict drug metabolism in vitro.

Translational research: Bridging the gap between preclinical and clinical research through translational studies facilitates the translation of experimental findings into clinical practice, informing personalized medicine approaches and improving patient outcomes.[88,89]

CONCLUSION

The exploration of pharmacokinetics and metabolism of benzothiazole and oxazolebased compounds unveils crucial insights with farreaching implications for drug discovery and development. Through a comprehensive analysis of absorption mechanisms, distribution patterns, metabolic pathways, and factors influencing pharmacokinetic properties, key determinants influencing the bioavailability, efficacy, and safety of these compounds have been elucidated. Strategies for improving pharmacokinetic properties, such as prodrug design and formulation optimization, emerge as potent avenues for enhancing drug delivery and systemic exposure. Furthermore, the paramount importance of metabolic stability in lead optimization underscores the need for early integration of metabolic assessments in drug development pipelines. As the field advances, continued research efforts in pharmacokinetics and metabolism are imperative to unravel complex drugmetabolite interactions and optimize therapeutic outcomes. A call to action is thus warranted, urging interdisciplinary collaboration and innovation to address existing challenges and propel the field forward. By harnessing the collective expertise of researchers and leveraging cuttingedge technologies, we can pave the way for the development of safer, more efficacious benzothiazole and oxazolebased therapeutics, ultimately improving patient care and advancing human health.

REFERENCES

1. Vidente, A. Cimmino, and M. Masi, "Phytotoxins produced by pathogenic fungi of grarian plants," Phytochem. Rev, 2019; 18: 843–870. doi: 10.1007/s11101-019-09624-0.
2. Y. F. Chen et al., "Design, synthesis and antibacterial activity of 1,3,4-oxadiazole sufones containing sulfonamide structure," Chin. J. Org. Chem, 2023; 43: 274–284. doi: 10.6023/cjoc202204068.
3. S. Leonard et al., "Plant–phytopathogen interactions: Bacterial responses to environmental and plant stimuli," Environ. Microbiol, 2016; 19: 1689–1716. doi: 10.1111/1462-2920.13611.
4. Q. Wei et al., "Discovery of novel dihydrolipoamide S-Succinyltransferase inhibitors based on fragment virtual screening," Int. J. Mol. Sci, 2021; 22: 12953. doi: 10.3390/ijms222312953.
5. J. X. Chen et al., "Recent research progress: Discovery of anti-plant virus agents based on natural scaffold," Front. Chem, 2022; 10: 926202,. doi: 10.3389/fchem.2022.926202.
6. G. R. Hernan, "Susceptibility genes to plant viruses," Viruses, 2018; 10: 484. doi: 10.3390/v10090484.
7. V. A. Gougherty and J. D. Jonathan, "Towards a phylogenetic ecology of plant pests and pathogens," Phil. Trans. R. Soc, 2021; 276: 20200359. doi: 10.1098/rstb.2020.0359.
8. Q. Wei et al., "Novel amide derivatives containing an imidazo[1,2-a]pyridine moiety: Design, synthesis as potential nematicidal and antibacterial agents," Pestic. Biochem. Physiol, 2021; 175: 104857. doi: 10.1016/j.pestbp.2021.104857.
9. R. N. Nagoshi and R. L. Meagher, "The Spodoptera frugiperda host strains: What they are and why they matter for understanding and controlling this global agricultural pest," J. Econ. Entomol, 2022; 115: 1729–1743. doi: 10.1093/jee/toac050.
10. L. Zhang et al., "Locust and Grasshopper Management," Annu. Rev. Entomol, 2019; 64: 15–34. doi: 10.1146/annurev-ento-011118-112500.
11. J. Wang et al., "Molecular cloning, characterization and functional analysis of GluCl from the oriental armyworm, Mythimna separata Walker," Pestic. Biochem. Physiol, 2019; 156: 56–62. doi: 10.1016/j.pestbp.2019.02.004.
12. B. Torto et al., "Management of cyst and root knot nematodes: A chemical ecology perspective," J. Agric. Food Chem, 2018; 66: 8672–8678. doi: 10.1021/acs.jafc.8b01940.
13. M. Bhat and S. L. Belagali, "Structural activity relationship and importance of benzothiazole derivatives in medicinal chemistry: A comprehensive review," Mini Rev. Org. Chem, 2020; 17: 323–350. doi: 10.2174/1570193X16666190204111502.
14. K. Lányi et al., "Effects of some naturally occurring substances on the photodegradation of herbicide methabenzthiazuron," J. Environ. Chem. Eng, 2016; 4: 123–129. doi: 10.1016/j.jece.2015.11.002.
15. K. S. Kyung et al., "Long-term fate of the herbicide mefenacet in a rice-grown lysimeter over a period of 6 consecutive years," J. Appl. Biol. Chem, 2015; 58: 35–43,. doi: 10.1007/s13765-015-0048-4.
16. L. H. Jin et al., "Synthesis, x-ray crystallographic analysis, and antitumor activity of N-(benzothiazole-2-yl)-1-(fluorophenyl)-O,O-dialkyl-alpha-aminophosphonates," Bioorg. Med. Chem. Lett, 2006; 16: 1537–1543. doi: 10.1016/j.bmcl.2005.12.041.
17. P. Bhatt et al., "Citrus Flavonoids: Recent Advances and Future Perspectives On Preventing Cardiovascular Diseases," in The Flavonoids, 2024; 131-152.
18. P. Bhatt et al., "Functional and tableting properties of alkali-isolated and phosphorylated barnyard

millet (Echinochloa esculenta) starch," ACS Omega, 2023; 8, 33: 30294–305.
19. P. Bhatt et al., "Plasma modification techniques for natural polymer-based drug delivery systems," Pharmaceutics, 2023; 15, 8: 2066.
20. S. M. Sondhi et al., "Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/benzoxazole derivatives and some Schiff's bases," Bioorg. Med. Chem. Lett, 2006; 14: 3758–3765. doi: 10.1016/j.bmc.2006.01.054.
21. I. Sigmundova et al., "Synthesis and study of new antimicrobial benzothiazoles substituted on heterocyclic ring," Arkivoc, 2008; 183–192. doi: 10.3998/ark.5550190.0009.815.
22. C. G. Mortimer et al., "Antitumor Benzothiazoles. 26. 2-(3,4-Dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a Simple Fluorinated 2-Arylbenzothiazole, Shows Potent and Selective Inhibitory Activity against Lung, Colon, and Breast Cancer Cell Lines," J. Med. Chem, 2006; 949: 179–185. doi: 10.1021/jm050942k.
23. S. R. Barik et al., "Persistence behavior of metamifop and its metabolite in rice ecosystem," Chemosphere, 2018; 193: 875–882. doi: 10.1016/j.chemosphere.2017.11.101.
24. W. Zhu et al., "Effects of 10%metamifop wp on gramineous weeds control in direct seeding paddy field," Weed Sci, 2011; 29: 62–64. doi: 10.19588/j.issn.1003-935x.2011.03.017.
25. P. Bhatt et al., "Development and characterization of fast dissolving buccal strip of frovatriptan succinate monohydrate for buccal delivery," Int J Pharm Investig, 2021; 11, 1: 69–75.
26. P. Bhatt et al., "Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery," The Chinese Journal of Artificial Intelligence, 2023.
27. P. Bhatt et al., "Blockchain technology applications for improving quality of electronic healthcare system," in Blockchain for Healthcare Systems, 2021; 97–113.
28. A. E. Smith, "Persistence and transformation of the herbicides [14C] fenoxaprop-ethyl and [14C] fenthiaprop-ethyl in two prairie soils under laboratory and field conditions," J. Agric. Food Chem, 1985; 33: 483–488. doi: 10.1021/jf00063a038.
29. X. Cai et al., "Mefenacet resistance in multiple herbicide-resistant Echinochloa crus-galli L. populations," Pestic. Biochem. Phys, 2022; 182: 105038. doi: 10.1016/j.pestbp.2022.105038.
30. Y. Liu et al., "A Novel fungicide benthiavalicarb-isopropyl," Agrochemicals, 2011; 50: 756–758. doi: 10.16820/j.cnki.1006-0413.2011.10.019.
31. Q. Bi and Z. Ma, "Sensitivity, resistance stability, and cross-resistance of Plasmopara viticola to four different fungicides," Crop Prot, 2016; 89: 265–272. doi: 10.1016/j.cropro.2016.07.030.
32. J. Wang et al., "Dufulin intervenes the viroplasmic proteins as the mechanism of action against southern rice black-streaked dwarf virus," J. Agric. Food Chem, 2019; 67: 11380–11387,. doi: 10.1021/acs.jafc.9b05793.
33. Z. Chen et al., "Dufulin activates HrBP1 to produce antiviral responses in tobacco," PLoS ONE, 2012; 7: e37944. doi: 10.1371/journal.pone.0037944.
34. X. Y. Li et al., "Research progress of structure biology of tobacco mosaic virus coat protein as molecular targets," Chin. J. Pestic. Sci, 2010; 12: 391–401. doi: 10.3969/j.issn.1008-7303.2010.04.03.
35. G. Ma et al., "Dufulin enhances salt resistance of rice," Pestic. Biochem. Physiol, 2022; 188: 105252. doi: 10.1016/j.pestbp.2022.105252.
36. V. Sareen, V. Khatri, U. Garg, P. Jain, K. Sharma, "Synthesis of Some New 2-(4-Nitrobenzothiazol-2′-ylamino)-4-(2-chloro-4-trifluoromethylanilino)-6-(substituted Thioureido)-1,3,5-triazines as Antifungal Agents," Phosphorus Sulfur Silicon Relat. Elem, 2007; 182: 2943–2948,. doi: 10.1080/10426500701544474.
37. S. Ahamed, P. Bhatt, S. J. Sultanuddin, R. Walia, M. A. Haque, and S. B. InayathAhamed, "An Intelligent IoT enabled Health Care Surveillance using Machine Learning," in International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI). IEEE, 2022.
38. V. Ahmed, S. Sharma, and P. Bhatt, "Formulation and evaluation of sustained release tablet of diltiazem hydrochloride," International Journal of Pharmaceutical Sciences and Research, 2020; 11, 5: 2193–2198.
39. A.E. Al-Snafi, S. Singh, P. Bhatt, and V. Kumar, "A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity," GSC biol pharm sci, 2022; 19, 3: 148–155.
40. B. Baskar, S. Ramakrishna, and A. Daniela La Rosa, Eds., Encyclopedia of green materials. Singapore: Springer Nature Singapore, 2022.
41. P. Bhatt et al., "Nanorobots recent and future advances in cancer or dentistry therapy- A review," Am J PharmTech Res, 2019; 9, 3: 321–331.
42. P. Bhatt et al., "Comparative study and in vitro evaluation of sustained release marketed formulation of aceclofenac sustained release tablets," Pharma Science Monitor, 2018; 9: 2.
43. P. Bhatt, "Mouth Dissolving Tablets Challenges, Preparation Strategies with a Special Emphasis on Losartan Potassium–A Review," World J. Pharm. Pharm. Sci, 2018; 7, 9: 271-287.
44. C. Goyal et al., "Estimation of shelf-life of Balachaturbhadrika syrup containing different sweetening agents," Res J Pharm Technol, 2022; 5078–5083.
45. T. Kaur and S. Singh, "Controlled release of bi-layered malvidin tablets using 3D printing techniques," J Pharm Res Int, 2021; 70–78.
46. M. Kaurav et al., "In-depth analysis of the chemical composition, pharmacological effects,

pharmacokinetics, and patent history of mangiferin," Phytomed Plus, 2023; 3: 2: 100445.
47. A. Kumar, P. Bhatt, and N. Mishra, "Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review," J Chem Pharm Sci, 2019; 12, 03: 71–78.
48. M. K. Malik et al., "Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices," Nat Prod J, 2022.
49. M. K. Malik et al., "Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice," ACS Omega, 2022; 7, 40: 35506–35514.
50. M. K. Malik et al., "Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility," ACS Omega, 2023; 8, 13: 11750–11767.
51. Pankaj, "Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy," J Pharm Res Int, 2021; 54–63.
52. Pankaj, "Cyclodextrin modified block polymer for oral chemotherapy," J Pharm Res Int, 2021; 21–29.
53. V. Raghuwanshi et al., "Recent Advances In Nanotechnology For Combating Against Corona Virus Infection," Journal of Pharmaceutical Negative Results, 2022; 1811-1820.
54. K. K. Sahu et al., "Utility of nanomaterials in wound management," in Nanotechnological Aspects for Next-Generation Wound Management, 2024; 101–130.
55. S. K. Sharma et al., "Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review," J Infect Public Health, 2022; 15, 5: 566–572.
56. S. K. Sharma and P. Bhatt, "Controlled release of bi-layered EGCG tablets using 3D printing techniques," J Pharm Res Int, 2021; 5–13.
57. S. K. Sharma and S. Singh, "Antimicrobial Herbal Soap Formulation," Journal of Pharmaceutical Research International, 2022; 32, 36: 82-88.
58. S. Singh et al., "Cardiovascular comorbidity of COVID-19 disease: A review," WJPMR, 2022; 8, 4: 216–225.
59. R. Johari et al., "Artificial Intelligence and Machine Learning in Drug Discovery and Development," in 2023 12th International Conference on System Modeling & Advancement in Research Trends (SMART), 2023; 12: 556-561.
60. X. Lv, X. Zhang, W. Tang, "Synthesis and antibacterial activity of cinnamic acyl thiourea derivatives," Appl. Chem, 2010; 25: 1286–1290. doi: 10.3969/j.issn.1000-0518.2008.11.008.
61. J. Weng, H. Huang, C. Ta, X. Liu, W. Chu, J. Chen, "Synthesis and antifungal activity of novel substituted-3-aryl-1,2,4-triazolo[3,4-b]benzothiazoles," Chin. J. Org. Chem, 2012; 32: 957. doi: 10.6023/cjoc1111162.
62. J. Weng, C. Tan, X. Liu, "Synthesis and fungicidal activity of hydrazones containing 4-methylbenzod]thiazole moiety," J. Pestic. Sci, 2012; 37: 164–168. doi: 10.1584/jpestics.G11-41.
63. H. Xiao, F. Wu, L. Shi, Z.W. Chen, S.H. Su, C.H. Tang, H.T. Wang, Z.N. Li, M.C. Li, Q.C. Shi, "Cinchona alkaloid derivative-catalyzed enantioselective synthesis via a Mannich-type reaction and antifungal activity of β-amino esters bearing benzoheterocycle moieties," Molecules, 2014; 19: 3955–3972. doi: 10.3390/molecules19043955.
64. Z. Zeng, Q. Huang, Y. Wei, Q. Huang, Q. Wang, "Synthesis, crystal structure and antibacterial activity of thiourea derivatives with benzothiazole-ring," Chem. Reagents, 2017; 39: 241–246. doi: 10.13822/j.cnki.hxsj.2017.03.005.
65. S. Singh et al., "Phytonutrients, Anthocyanidins, and Anthocyanins: Dietary and Medicinal Pigments with Possible Health Benefits," in Advances in Flavonoids for Human Health and Prevention of Diseases, 2024; 23-46.
66. S. Singh et al., "Digital Transformation in Healthcare: Innovation and Technologies," in Blockchain for Healthcare Systems, 2021; 61–79.
67. S. Singh et al., "Alginate based Nanoparticles and Its Application in Drug Delivery Systems," Journal of Pharmaceutical Negative Results, 2022; 1463-1469.
68. X. Huo, W. Li, B. Zhang, X. Chen, Y. Zhou, J. Zhang, X. Han, B. Dai, "Synthesis and fungicidal evaluation of novel β-carboline benzimidazole and β-carboline-benzothiazole hybrids," Chin. J. Org. Chem, 2018; 38: 3356–3362. doi: 10.6023/cjoc201805053.
69. R.K. Upadhyay, K.K. Saini, N. Deswal, T. Singh, K.P. Tripathi, P. Kaushik, N.A. Shakil, A.C. Bharti, R. Kumar, "Synthesis of benzothiazole-appended bis-triazole-based structural isomers with promising antifungal activity against Rhizoctonia solani," RSC Adv, 2022; 12: 24412–24426. doi: 10.1039/D2RA04465J.
70. R.A.C. Jones, "Global plant virus disease pandemics and epidemics," Plants, 2021; 10: 233. doi: 10.3390/plants10020233.
71. Y. Liu, J. Chen, D. Xie, B. Song, D. Hu, "First report on anti-TSWV activities of quinazolinone derivatives containing a dithioacetal moiety," J. Agric. Food Chem, 2021; 69: 12135–12142. doi: 10.1021/acs.jafc.1c03171.
72. He, J. Shi, Y. Wang, S. Wang, J. Chen, X. Gan, B. Song, D. Hu, "Synthesis, Antiviral activity, and mechanisms of purine nucleoside derivatives containing a sulfonamide moiety," J. Agric. Food Chem, 2019; 67: 8459–8467. doi: 10.1021/acs.jafc.9b02681.
73. S. Tatineni, G.L. Hein, "Plant viruses of agricultural importance: Current and future perspectives of virus disease management strategies," Phytopathology, 2023; 113: 117–141. doi: 10.1094/PHYTO-05-22-0167-RVW.

74. I.P. Calil, E.P. Fontes, "Plant immunity against viruses: Antiviral immune receptors in focus," Ann. Bot, 2017; 119: 711–723. doi: 10.1093/aob/mcw200.
75. Q.Z. Xiao, B. Deng, H.L. Zou, Q.J. Teng, Z.C. Zhou, "Study progress in biological prevention of plant virus," South China Agric, 2021; 15: 64–69. doi: 10.19415/j.cnki.1673-890x.2021.34.014.
76. W.X. Yu, J.Z. Shen, "An overview on plant viral diseases and antiviral agents," World Pestic, 2021; 43: 17–24. doi: 10.16201/j.cnki.cn10-1660/tq.2021.05.03.
77. J. Zhang, F. He, J. Chen, Y. Wang, Y. Yang, D. Hu, B. Song, "Purine nucleoside derivatives containing a sulfa ethylamine moiety: Design, synthesis, antiviral activity, and mechanism," J. Agric. Food Chem, 2021; 69: 5575–5582. doi: 10.1021/acs.jafc.0c06612.
78. D. Jiang, J. Chen, N. Zan, C. Li, D. Hu, B. Song, "Discovery of novel chromone derivatives containing a sulfonamide moiety as anti-ToCV agents through the tomato chlorosis virus coat protein-oriented screening method," Bioorg. Med. Chem. Lett, 2021; 53: 128431. doi: 10.1016/j.bmcl.2021.128431.
79. X. Han, P.C. Zheng, C.P. Tang, Y. Xie, F. Wu, J. Song, J. Zhao, Z.N. Li, M.C. Li, "Synthesis and anti-TMV activity of dialkyl/dibenzyl 2-((6-substituted-benzod]thiazol-2-ylamino)(benzofuran-2-yl)methyl) malonates," Molecules, 2013; 18: 13623–13635,. doi: 10.3390/molecules181113623.
80. H. Xiao, P. Li, D. Hu, B.A. Song, "Synthesis and anti-TMV activity of novel β-amino acid ester derivatives containing quinazoline and benzothiazole moieties," Bioorg. Med. Chem. Lett, 2014; 24: 3452–3454. doi: 10.1016/j.bmcl.2014.05.073.
81. Y.Y. Yao, X. Zhang, S.X. Chen, M.M. Xing, H. Shu, B.C. Tang, W. Xue, "Synthesis of benzothiazol-β-amino acid esters derivatives applied to research of anti-TMV," Molecules, 2016; 32: 320–326. doi: 10.13563/j.cnki.jmolsci.2016.04.009.
82. P. Zhang, C. Tang, Z. Chen, B. Wang, X. Wang, L. Jin, S. Yang, D. Hu, "Design, synthesis, and antiviral activity of α-aminophosphonates bearing a benzothiophene moiety," Phosphorus Sulfur Silicon Relat. Elem, 2014; 189: 530–540. doi: 10.1080/10426507.2013.829837.
83. D. Xie, A. Zhang, D. Liu, L. Yin, J. Wan, S. Zeng, D. Hu, "Synthesis and antiviral activity of novel α-aminophosphonates containing 6-fluorobenzothiazole moiety," Phosphorus Sulfur Silicon Relat. Elem, 2017; 192: 1061–1067. doi: 10.1080/10426507.2017.1323895.
84. J. Tian, R. Ji, H. Wang, S. Li, G. Zhang, "Discovery of novel α-aminophosphonates with hydrazone as potential antiviral agents combined with active fragment and molecular docking," Adv. Novel Nat. Prod. Pestic, 2022; 10: 2296–2646. doi: 10.3389/fchem.2022.911453.
85. L. Liu, B. Song, P.S. Bhadury, D. Hu, S. Yang, "Synthesis and bioactivities of α-aminophosphonate derivatives containing benzothiazole and thiourea moieties," Phosphorus Sulfur Silicon Relat. Elem, 2012; 187: 61–70,. doi: 10.1080/10426507.2011.575422.
86. S. Yang, B. Song, X. Liu, L. Pang, L. Jin, H. Wang, D. Hu, G. Liu, "Synthesis and anti-tmv activity of 2-(benzod]thiazol-2-ylthio)-1-(2,3,4-trimethoxyphenyl) ethanoxime ester and ether derivatives," Chin. J. Org. Chem, 2005; 25: 1116–1120. doi: 10.3321/j.issn:0253-2786.2005.09.021.
87. Ouyang, B. Song, D.Y. Hu, "A novel synthesis of (E)-3-methylthio-3-substituted arylamino-2-cyanoacrylates under microwave irradiation," Molecules, 2005; 10: 1351–1357. doi: 10.3390/10101351.
88. W. Xue, H. Li, H. Fan, Z. Xiong, Y. He, H. Qi, "Synthesis and biological activity of anthranilic diamides compounds containing fluorine and benzothiazole unites," J. Univ. Jinan Sci. Tech, 2012; 26: 353–357.
89. Z.B. Wang, X.S. Zhu, M. Liu, X. Zhang, W. Xue, "Synthesis and biological activity of oxime ethers of curcumin derivatives," Chin. J. Org. Chem, 2014; 34: 1662. doi: 10.6023/cjoc201402035